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Abstract
Purpose The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell
cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [89Zr]Zr-DFO-girentuximab-PET/CT
and [18F]FDG-PET/CT in detecting ccRCC lesions in patients with a good or intermediate prognosis metastatic clear cell renal
cell carcinoma (mccRCC) according to the International Metastatic Database Consortium (IMDC) risk model.
Methods Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis,
eligible for watchful waiting, were included. Patients underwent CT, [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/
CTat baseline. Scans were independently reviewed and lesions of ≥10mm and lymph nodes of ≥15mm at CTwere analyzed. For
lesions with [89Zr]Zr-DFO-girentuximab or [18F]FDG-uptake visually exceeding background uptake, maximum standardized
uptake values (SUVmax) were measured.
Results A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25–12.75) of which 42% were in lung,
22% in lymph nodes and 10% in bone. Combined [89Zr]Zr-DFO-girentuximab-PET/CT and CT detected more lesions than CT
alone: 91% (95%CI: 87–94) versus 56% (95%CI: 50–62, p = 0.001), respectively, and more than CT and [18F]FDG-PET/CT
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combined (84% (95%CI:79–88, p < 0.005). Both PET/CTs detected more bone and soft tissue lesions compared to CT alone.
Conclusions The addition of [89Zr]Zr-DFO-girentuximab-PET/CT and [18F]FDG-PET/CT to CT increases lesion detection
compared to CT alone in newly diagnosed good and intermediate prognosis mccRCC patients eligible for watchful waiting.
Keywords CAIX . Clear cell renal cell carcinoma . FDG . Girentuximab . Imaging . PET
Introduction
Renal cell carcinoma (RCC) accounts for 2% of all malignan-
cies worldwide, with an estimated 403,262 new cases in 2018.
Seventy percent have a clear cell component. Metastatic clear
cell (mcc) RCC has a variable course, with a subgroup of
patients showing slow disease progression. In those patients,
it is safe to observe the course of disease in a period of so-
called watchful waiting, avoiding unnecessary side-effects
and costs of systemic treatment.
To identify patients eligible for watchful waiting, prognos-
tic schemes such as the International Metastatic Database
Consortium (IMDC) risk model have been used to differenti-
ate between patients with a good, intermediate or poor prog-
nosis [1, 2]. For staging mRCC, European Society of Medical
Oncology (ESMO) guidelines mandate contrast-enhanced
computed tomography (CT) of chest, abdomen and pelvis [3].
Previously, an international phase II study in mRCC pa-
tients eligible for watchful waiting showed that higher num-
bers of IMDC adverse risk factors (p = 0.0403) and higher
numbers of metastatic disease organ sites (p = 0.0414) were
associated with a shorter period of watchful waiting [4]. These
results substantiate the clinical value of imaging, which may
be further enhanced by molecular imaging with [18F]FDG or
emerging radiopharmaceuticals targeting tumor-associated
antigens like carbonic anhydrase IX (CAIX) to identify pa-
tients in need of urgent systemic or local therapy.
CAIX is over-expressed in 94% of ccRCC-tumors due to a
mutational loss of Von Hippel Lindau protein [5–7].
Prognostic implications of immunohistochemically deter-
mined CAIX-expression are unequivocal [7–12]. In-vivo as-
sessment of CAIX-expression can be performed with
radiolabeled girentuximab (anti-CAIX antibody) PET-imag-
ing. This technique visualizes primary and metastatic ccRCC
lesions [13–15]. The value of [18F]FDG-PET/CT combined
with CT in diagnosing and staging mRCC is not established;
however, [18F]FDG-PET/CTmay have prognostic value, with
a positive scan being unfavourable [16, 17]. The IMaging
PAtients for Cancer drug selecTion (IMPACT)-RCC study
(ClinicalTrials.gov: NCT02228954) was designed to assess
the added value of [89Zr]Zr-DFO-girentuximab-PET/CT and
[18F]FDG-PET/CT at presentation in predicting the duration
of watchful waiting in patients with good or intermediate
prognosis mccRCC.
Here, we report the lesion detection of [89Zr]Zr-DFO-
girentuximab-PET/CT and [18F]FDG-PET/CT in mccRCC
in addition to CT. We determined the lesion detection yield
of the three modalities, assessed inter-observer agreement in
[89Zr]Zr-DFO-girentuximab-uptake interpretation, and inves-
tigated determinants of quantitative [89Zr]Zr-DFO-
girentuximab and [18F]FDG-uptake.
Materials and methods
Patients
In this prospective multicenter cohort study, patients aged
18 years and older with histologically or cytologically proven
RCC with a clear cell component, recently (<6 months) diag-
nosed metastases, and a good or intermediate prognosis accord-
ing to IMDC score [1], were enrolled in the IMPACT-RCC
study conducted at four Dutch academic medical centers. A
period of watchful waiting for 2 months was considered option-
al according to treating medical oncologist. Patients who re-
ceived any previous systemic treatment for RCC in any setting
were excluded, but previous radiotherapy and surgery (nephrec-
tomy or metastasectomy) was permitted. Furthermore, patients
were excluded in the presence of untreated central nervous
system metastases or symptomatic intra-cerebral metastases,
pregnant or breast feeding women. Only patients without prior
systemic treatment were enrolled, therefore the IMDC criteria
‘time from diagnosis to treatment <1 year’ was adapted into
‘time from primary diagnosis to diagnosis of metastatic disease
<1 year’. Watchful waiting was terminated if radiological dis-
ease progression was established, in combination with a clinical
need to start systemic treatment.
Patient imaging
Patients underwent CT, [18F]FDG and [89Zr]Zr-DFO-
girentuximab-PET/CT at the start of the watchful waiting pe-
riod. Further details on the imaging modalities (acquisition
and reconstruction protocols) and the conjugation,
radiolabeling and quality control of [89Zr]Zr-DFO-
girentuximab are provided in the Supplements.
Image assessment
All CT and [18F]FDG-PET/CT scans were reported according
to standard clinical practice by an experienced local radiolo-
gist and nuclear physician, respectively. The assessment of CT
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lesions was performed according to RECIST 1.1 [18]; how-
ever, to ensuremeasurements and documentation of all lesions
including non-target lesions of ≥10 mm, CT scans were inde-
pendently revised by one or two experienced radiologists
(E.H.A; T.C.K.). The [89Zr]Zr-DFO-girentuximab PET/CTs
were assessed in a central reviewing system to ensure true
lesion detection and reproducible inter-observer agreement.
All [89Zr]Zr-DFO-girentuximab PET/CTs were assessed
by three expert nuclear physicians independently (W.O.;
A.H.B.; O.H.) through online central reviewing system de-
signed by CTMM TRaIT. The three reports were harmonized
to one final report by one designated reviewer. In case of
different findings, a meeting was organized to reach consen-
sus. The treating physician was blinded for the results of either
PET/CT; however, for patient safety reasons, the nuclear phy-
sician was allowed to communicate findings that required
(local) interventions (e.g. brain metastases).
A tumor lesion was defined visually positive based on ana-
tomical substrate on low-dose CT in combination with [18F]-
FDG and/or [89Zr]Zr-DFO-girentuximab-uptake, or solely on
prominent, non-physiological antibody-uptake. Quantification
of positive lesions as defined by evaluation reports for
[18F]FDG and [89Zr]Zr-DFO-girentuximab-PET/CT was per-
formed by drawing regions-of-interest using Inveon Research
Workplace software (IRW, version 4.1). The maximum and
mean standardized uptake values (SUV) were calculated.
SUVmax was used for tumor tracer-uptake; SUVmean for mea-
suring uptake in healthy organs and blood pool.
Statistical analysis
To compare the agreement in individual lesion detection be-
tween observers, we used dependent pair wise or multi-
observers kappa-coefficients with the delta method [19].
Lesion detection rates per imaging modality and combined
imaging modalities (CT combined with PET/CT) were esti-
mated and compared (by Wald tests) using mixed effect logis-
tic regression models accounting for within patient and lesion-
clustering by random intercepts. We evaluated lesion detec-
tion rates overall and according to organ sites. Furthermore,
we compared the median number of affected organ sites
across patients assessed by CT only, or in conjunction with
either PET/CT using Wilcoxon signed rank tests.
To assess biodistribution of [89Zr]Zr-DFO-girentuximab,
we estimated the average SUVmean per organ and compared
variability within and between patients (one-sample T-test).
SUVmax was evaluated using descriptive methods besides
mixed effects linear regression models, taking within patient
clustering into account as random intercepts (using intra-class
correlation coefficient (ICC) to estimate variation in uptake
due to between-patient heterogeneity). These models were
also used to assess determinants of tracer-uptake (introduced
as fixed effects and compared by Wald tests). SUVmax was
natural log-transformed to obtain appropriate model fit,
resulting in geometric means or percent changes in SUVmax
as interpretation of fixed effects. We fitted these models under
restricted maximum likelihood using Satterthwaite approxi-
mations to degrees of freedom. We used the marginal R2 to
estimate the variance in tracer-uptake explained by the fixed
effects of these models [20], then fitted under maximum
likelihood.
We report estimates with 95% confidence intervals (CI),
and statistical tests were two-sided with threshold for signifi-
cance of 5%, without adjusting for multiple testing. Analyses
were performed in R (version 3.2.1), particularly using librar-
ies multi-agree (version 2.1), lme4 (version1.1-11), lmerTest
(version2.0-20), and MuMIn (version1.10.0).
Results
Patients
From February 2015 until March 2018, 42 mccRCC patients
were included. All patients had a histopathological diagnosis
of the primary tumor, either through (partial) nephrectomy or
biopsy in 36 and six patients, respectively. A total of 14 pa-
tients had a favourable prognosis. Of the remaining 28 pa-
tients, 13 had a predicted intermediate prognosis with one risk
factor and 15 patients with two risk factors. This was primarily
due to the diagnosis of metastases <1 year after the primary
diagnosis (80%) and/or the presence of anaemia (51%). There
was no correlation between histology (e.g. mixed vs. pure
clear cell) and the estimated prognosis according to IMDC.
All patients without a previous nephrectomy had an esti-
mated intermediate prognosis. In total 57% of all patients pre-
sented with metachronous metastases at a median interval of
0.7 (range 0–15) months between primary diagnosis and first
metastasis. One patient presented with only sub-centimeter
indeterminate lung lesions; therefore, lesions were not includ-
ed in the analyses. Five others had a negative [18F]FDG-PET/
CT, of whom one plus two other patients had a negative
[89Zr]Zr-DFO-girentuximab-PET/CT. In two patients, the
[18F]FDG-PET/CT and/or [89Zr]Zr-DFO-girentuximab-PET/
CT revealed brain metastases warranting local treatment with
stereotactic radiotherapy and temporary treatment with
corticosteroids.
Patient characteristics are shown in Table 1, imaging ex-
amples are shown in Fig. 1.
Lesion detection rates of CT, [18F]FDG and [89Zr]
Zr-DFO-girentuximab-PET/CT
A total of 449 lesions were identified by at least one modality
(median per patient, 7; ICR 4.25–12.75). Lesions were located
in lung (42%), lymph nodes (22%), bone (10%), soft tissue
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(8%), adrenal gland (6%), kidney (4%), pancreas (4%) or
elsewhere (4%).
Lesion detection rates differed across modalities: 56% was
visualized by CT (95%CI 50–62). [18F]FDG-PET/CT detect-
ed 59% (95%CI 53–65; p = 0.37). [89Zr]Zr-DFO-
girentuximab-PET/CT visualized 70% (95%CI 64–75), which
was more than CT alone (p < 0.001) or [18F]FDG-PET/CT
alone (p < 0.005). Nine of 449 (2%) lesions were outside the
field of view of CT (brain n = 2; lymph nodes in the neck n =
4, bone (extremities) n = 3). Agreement in detecting lesions
between modalities was poor; kappa’s −0.12 (95%CI
−0.25;0.01), −0.00 (95%CI −0.13;0.12), and 0.20 (95%CI
0.02;0.37) for CT and [89Zr]Zr-DFO-girentuximab-PET/CT,
CT and [ 18F ]FDG-PET/CT, and [89Zr ]Zr-DFO-
girentuximab-PET/CT and [18F]FDG-PET/CT, respectively.
Agreement between two radiologists in identifying lesions
on CT was moderate (kappa 0.51; 95%CI 0.42–0.59), and
substantial for three nuclear physicians assessing [89Zr]Zr-
DFO-girentuximab-PET/CTs (kappa 0.71; 95%CI 0.60–
0.82).
Combination of modalities for lesion detection
With the addition of [89Zr]Zr-DFO-girentuximab-PET/CTand
[18F]FDG-PET/CT, lesion detection by CT alone increased
from 56% to 91% (95%CI 87–94) and 84% (95%CI 79–88),
respectively. Improved lesion detection rate was apparent for
all organ sites (Fig. 2). The lesion detection of CT-[89Zr]Zr-
DFO-girentuximab-PET/CT was better than CT-[18F]FDG-
PET/CT (p < 0.005). Largest improvement was seen in the
number of bone lesions, with 81% of all bone lesions detected
by both [89Zr]Zr-DFO-girentuximab-PET/CT and CT as well
as [18F]FDG-PET/CTwith CT, compared to 16% by CTalone
(p < 0.001). More lung lesions were detected by CT-[89Zr]Zr-
DFO-girentuximab-PET/CT compared to CT-[18F]FDG-PET/
CT [95% (95%CI 91–98)] versus 84% (95%CI 76–89; p <
0.001). Lesion detection approached 100% in pancreas and
kidney with combined CT and [89Zr]Zr-DFO-girentuximab-
PET/CT. Conversely, detecting enlarged lymph nodes was
better with combined [18F]FDG-PET/CT and CT [94%
(95%CI 88–97)], compared to [89Zr]Zr-DFO-girentuximab-
PET/CT and CT [83% (95%CI 73–89, p < 0.05)].
Assessment of affected organ sites
The median number of affected organ sites increased with the
addition of [89Zr]Zr-DFO-girentuximab-PET/CT or
[18F]FDG-PET/CT compared to CT alone in 27 patients (me-
dian increased from 2 to 3, range 1–7 (p < 0.005). [89Zr]Zr-
DFO-girentuximab-PET/CT and [18F]FDG-PET/CT per-
formed similarly (Table 2). Patients were categorized accord-
ing to the location of their lesions (e.g. lung only; other or-
gan(s) only and both lung and other organs). With the addition
of both PET/CTs, two patients were re-categorized from lung
only into ‘both lung and other organs’ based on the additional
detected lymph node and bone lesions (Table 1).
Quantitative analysis of [89Zr]Zr-DFO-girentuximab
and [18F]FDG-uptake
In normal tissues the highest [89Zr]Zr-DFO-girentuximab-up-
take was observed in healthy liver (geometric mean SUVmean
6.7 (95%CI 6.4–7.3), lowest in healthy lung (geometric mean
SUVmean 1.1 (95%CI 0.8–1.2) (p < 0.05). The physiological
biodistribution of [89Zr]Zr-DFO-girentuximab is illustrated in
the Supplements.
The overall geometric mean [89Zr]Zr-DFO-girentuximab
SUVmax in lesions was 15.5 (95%CI 12.5–19.2), and 4.4
(95%CI 3.8–5.1) for [18F]FDG. Tracer uptake was higher in
lesions with a CT diameter > 15 mm, compared to smaller
lesions (geometric mean SUVmax 23.9 (95%CI 19.0–30.0)
Table 1 Patient demographics and clinical characteristics
Parameter Patients (n = 42)
Sex
Male 31 (74%)
Female 11 (26%)
Age (years)
Median (range) 66.1 (44–86)
Nephrectomy
Yes 36 (86%)
No 6 (14%)
Histology
Pure clear cell 32 (76%)
Mixed 10 (24%)
Location of first metastasesa
Lungb 22 (52%)
Adrenal gland 4 (10%)
Lymph node 9 (21%)
Bone 2 (5%)
Kidney 2 (5%)
Otherc 3 (7%)
Time from diagnosis to first metastases (median 0.7; range 0–15 months)
<1 year 23 (55%)
≥1 year 19 (45%)
IMDC risk factors
0 (favorable) 14 (33%)
1 (intermediate) 13 (31%)
2 (intermediate) 15 (36%)
a 57% presented with synchronous metastases
b Five patients had lung-only disease (based on CT only).
c Two patients presented with soft tissue metastases, one patient with
multiple involved organ sites
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and 5.8 (95%CI 5.0–6.8 for 89Zr-DFO-girentuximab and geo-
metric mean 11.6 (95%CI 9.3–14.5) and 3.5 (95%CI 3.0–4.1)
for [18F]FDG). Based on expert opinion, for further analyses
of tracer uptake a cut-off of ≥15 mm in diameter on CT was
chosen to avoid partial volume effects thwarting proper quan-
tification (leaving 95 lesions in 26 patients for [89Zr]Zr-DFO-
girentuximab, and 93 lesions in 29 patients for [18F]FDG).
The [89Zr]Zr-DFO-girentuximab SUVmax varied greatly,
ranging from 3.8 to 230.8, with a median-fold difference of
2.8 (range 1.2–15.3) per patient. Inter-patient heterogeneity
accounted for 41% of variation in [89Zr]Zr-DFO-
girentuximab SUVmax, and 53% for [
18F]FDG SUVmax (i.e.
ICC of 0.41 and 0.53, respectively). Highest [89Zr]Zr-DFO-
girentuximab-uptake was seen in kidney and adrenal gland
Fig. 1 On the left are transversal sections of one patient of CT, [89Zr]Zr-
DFO-girentuximab and [18F]FDG-PET/CT. The red circle represents an
adrenal gland lesion in a patient as visualized by CT (a), [89Zr]Zr-DFO-
girentuximab (b) and [18F]FDG-PET/CT (c), respectively. On the right,
MIP images of [89Zr]Zr-DFO-girentuximab (d) and [18F]FDG-PET/CT
(e) are presented
Fig. 2 Lesion detection per
imaging modality and per organ.
Concordant pairs were lesions
that were visualized on all three
modalities. Nine PET detected
lesions were outside the field of
view of CT. *p < 0.001 compared
to CT only
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lesions (median SUVmax 61.1 and 69.9, respectively) and low-
est in lung lesions (median SUVmax 9.4) (Fig. 3). Two out of
six patients without prior nephrectomy showed highest
[89Zr]Zr-DFO-girentuximab-uptake at primary site (SUVmax
70.52 and 40.48), compared to synchronous metastatic sites.
Determinants of tracer-uptake
[18F]FDG-uptake was not related to [89Zr]Zr-DFO-
girentuximab-uptake (p = 0.29). Univariable-analysis showed
a strong relation of tracer-uptake to lesion location (p < 0.005;
explaining 61% and 12% of the variation in [89Zr]Zr-DFO-
girentuximab and [18F]FDG SUVmax). Largest measured CT
lesion diameter was associated with tracer-uptake (p < 0.001,
explaining 13% and 16% of the variation in [89Zr]Zr-DFO-
girentuximab and [18F]FDG SUVmax), with [
89Zr]Zr-DFO-
girentuximab SUVmax increasing on average 59% (95%CI
25–102) and [18F]FDG SUVmax 33% (95%CI 14–54) per
doubling diameter.
Inmultivariable analysis, mutual adjustment for location, size,
and uptake of the other tracer did not substantially alter the cor-
relation between tracer uptake and location. Size and [89Zr]Zr-
DFO-girentuximab SUVmax were no longer related [estimated
average change in uptake of 3% (95%CI −17 to 28) per doubling
size], whereas the relation between size and [18F]FDG SUVmax
did not change substantially [estimated change in uptake of 32%
(95%CI 11–58) per doubling size]. Thus, [89Zr]Zr-DFO-
girentuximab-uptake was mainly dependent on lesion location,
and little affected by size and uptake of the [18F]FDG (which
together explained 63% compared to 61% by location alone).
Discussion
This lesion detection analysis in newly diagnosed mccRCC
patients with a good or intermediate prognosis according to
IMDC criteria and eligible for watchful waiting, demonstrates
that addition of [89Zr]Zr-DFO-girentuximab-PET/CT to CT in
the diagnostic work-up increases overall detection of mccRCC
lesions from 56% to 91%. The number of detected bone- and soft
tissue lesions increased, and all renal and pancreatic lesions were
detected with this combination of modalities. In this patient se-
lection, [89Zr]Zr-DFO-girentuximab-PET/CT and CT resulted in
the detection of more mccRCC lesions than [18F]FDG-PET/CT
and CT (p = 0.006). Considering the expected proportion of
false-positive lymph node lesions on [18F]FDG-PET/CT due to
[18F]FDG uptake in reactive (mostly mediastinal) lymph nodes,
this difference in detection rate is in favour of [89Zr]Zr-DFO-
girentuximab-PET/CT and CT.
A patient’s prognosis is estimated based on the number of
involved organs onCT, total disease burden and period ofwatch-
ful waiting, rather than the number of lesions [4, 21]. In our study
population 33% of the patients present with a predicted good
prognosis mRCC and 43% of patients with synchronous metas-
tases. This is comparable to previous datasets and reflects daily
clinical practice [4]. Patients with lung-only metastases are
thought to have a better prognosis than other involved organ
sites such as liver and bone [22, 23]. In our study population,
based on CT only, seven patients (17%) presented with lung-
only metastases. This number was revised after the addition of
PET/CT because of the detection of additional bone and lymph
node lesions by PET/CT in two patients. Furthermore, two pa-
tients were diagnosed with brain metastases by [89Zr]Zr-DFO-
girentuximab PET/CT that required local treatment.
Overall, the median number of two involved organs per
patient as determined by CT alone increased to three per pa-
tient with the addition of PET/CT (range 1–7; p < 0.005), even
without adjusting for the limited CT field-of-view. This is
largely attributed to the detection of more soft-tissue and bone
lesions, a well-known limitation of CT due to less soft tissue
contrast and the limited ability to detect (non-lytic) bone le-
sions. This limited increase in the number of involved organ
sites with the addition of PET/CT questions its additional val-
ue, since solely an increase in detection lesions will not lead to
the implementation of [89Zr]Zr-DFO-girentuximab or
[18F]FDG-PET/CT to our standard work-up. However,
Table 2 The number of affected
organ sites per patient per
imaging modality (combination)
Number of organ sites with metastases per patient
CT only (median 2) [18F]FDG-PET/CT and CT
(median 3)*
[89Zr]-DFO-girentuximab-PET/CT and CT
(median 3)*
0 2.4% – –
1 33.3% 23.8% 23.8%
2 35.7% 21.4% 26.1%
3 21.4% 38.1% 30.9%
4 7.1% 14.2% 11.9%
5 – 2.4% 4.8%
7 – – 2.4%
*Significant increase of the median number of organ sites compared to CT alone (p < 0.005)
1936 Eur J Nucl Med Mol Imaging (2019) 46:1931–1939
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT findings
were clinical and possibly prognostic relevant in at least 10%
of patients and warrants further investigation.
The interpretation of involved organ sites in all three mo-
dalities was challenging, especially considering the limitation
of each modality. For example, spatial resolution is lower with
PET/CT compared to CT, resulting in a partial volume effect
affecting small (<2 cm), low-contrast lesions both visually and
quantitatively [24]. CT can detect sub-centimeter or indeter-
minate pulmonary nodules and lymph nodes, although
distinguishing nonspecific from small metastatic lesions with
CT is notoriously difficult. Based on studies of pulmonary
metastases in RCC and RECIST 1.1 criteria, we used a diam-
eter cut-off of 10 mm and in lymph nodes 15 mm to prevent
overestimating of the number of detected lesions [25, 26].
This ultimately reduced the number of (small) lung and lymph
node lesions detected by CT, thereby underestimating the
overall lesion detection by CT.
All lesions visible on either CT, [89Zr]Zr-DFO-girentuximab
or [18F]FDG-PET/CT were defined as metastases, which intro-
duces potential bias and a risk of possible false-positive. Despite
the high specificity of [89Zr]Zr-DFO-girentuximab to visualize
primary and metastatic ccRCC-lesions expressing CAIX [5,
13–15, 27] and the careful assessment of [89Zr]Zr-DFO-
girentuximab PET/CT by three independent nuclear physicians
with a fairly good agreement (kappa 0.71;95%CI:0.60–0.82),
our results are limited by the lack of histological confir-
mation of the detected lesions. Lesions not visible on CT
but only [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/
CT could be false-positive lesions. Alternatively, the
tracer-uptake may resemble a new tumor lesion that is
not yet visible on CT due to a dedifferentiated state with
a different metabolic state and could become apparent in
a period of follow-up. Finally, false negative lesions
could be present as well; however, with the available data
we cannot draw any conclusions on this.




Fig. 3 AViolin plot of actual
distribution of [89Zr]Zr-DFO-
girentuximab and [18F]FDG
SUVmax in tumor lesions per
organ site. Black vertical lines are
95% CIs of geometric mean
SUVmax, white dots within black
lines and values are the actual
geometric means; coloured dots
are individual metastases. The
locations represent organ sites
with at least five suspect lesions.
*Compared to lung lesions, a
difference was seen in the height
of [89Zr]Zr-DFO-girentuximab
SUVmax values of lymph node,
soft tissue, adrenal gland and
kidney lesions (p < 0.05). **The
height of [18F]FDG SUVmax
values of kidney lesions was
significantly higher compared to
soft tissue lesions (p < 0.05)
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Interestingly, [18F]FDG and [89Zr]Zr-DFO-girentuximab-
uptake strongly depend on the organ where the lesion is local-
ized, which is also previously described for [89Zr]Zr-
bevacizumab uptake in mccRCC [28]. Overall, highest
[18F]FDG and [89Zr]Zr-DFO-girentuximab SUVmax values
were visualized in metastases of the adrenal gland and
the kidney. In the six patients without previous nephrecto-
my, the highest SUVmax value was measured in the meta-
static lesions and not in the primary tumor. Organ-specific
characteristics influence [89Zr]Zr-DFO-girentuximab-up-
take, e.g. presence of stromal and immune cells, stroma
and/or vasculature affecting perfusion. This is illustrated
by the notably high SUVmax values of [89Zr]Zr-DFO-
girentuximab uptake in adrenal gland lesions as compared
to other lesion sites, e.g. lung (median SUVmax 69.9 and
9.4, respectively).
Depending on the clinical question, both [89Zr]Zr-DFO-
girentuximab and [18F]FDG-PET/CT are valuable as addi-
tional imaging techniques by visualizing whole-body
mccRCC lesions where the combination of [89Zr]Zr-
DFO-girentuximab with CT increases the total number of
detected lesions most and supports the role of [89Zr]Zr-
DFO-girentuximab-PET/CT in the early detection of
mccRCC lesions [27]. Furthermore, the quantification of
tracer-uptake in both PET-imaging modalities offers a bet-
ter understanding of the heterogenic study population [4].
Combining anatomical imaging techniques with functional
imaging techniques targeting glucose metabolism and
CAIX expression offers a better representation of the het-
erogeneity by visualizing whole body tumor nature and
active metabolic processes (e.g. glycolysis, GLUT-1-ex-
pression) [8].
Upon completion of the follow-up data of all patients in-
cluded in the IMPACT-RCC study, we will analyze whether
[89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT contrib-
utes to a better prediction of the course of disease during
watchful waiting in good and intermediate prognosis
mccRCC patients.
Conclusions
The addition of [89Zr]Zr-DFO-girentuximab-PET/CT and
[18F]FDG-PET/CT to CT increases lesion detection compared
to CT alone in newly diagnosed good and intermediate prog-
nosis mccRCC patients eligible for watchful waiting. The
quantitative analyses of 89Zr-DFO-girentuximab and
[18F]FDG-uptake can be relevant in clinical practice, as site-
specific heterogeneity may require a different treatment
approach.
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